Main Menu

Diagnostic biomarkers

The Institute of Cancer Research currently has a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators. 

Monoclonal antibodies against Cerb-B2

ICR collaboration and licensing opportunity.
Principal Scientists: Dr Steve Hobbs and Dr Suzanne Eccles

A panel of rat anti-Cerb-B2 antibodies has been developed and is now available for diagnostic and therapeutic applications. Extensive preclinical evaluation has been completed.

For further information contact Jonathan Beech or download the PDF flyer.

Monoclonal antibodies against EGFR

ICR licensing opportunity.
Principal Scientist: Dr Suzanne Eccles

A set of rat monoclonal anti-EGFR antibodies has been developed and are available for diagnostic and therapeutic applications. Extensive preclinical characterisation completed. One antibody has completed phase I Clinical trials.

For further information contact Jonathan Beech or download the PDF flyer.

Anti-KSR monoclonal antibody

Cancer Research Technology licensing opportunity.
Principal Scientist: Professor Richard Marais

Clone name: MINT/1/4 Host species: rat Ig isotype: IgG2a Immunogen: Full length mouse KSR-GST fusion Protein Antibody available for licensing.

For more information contact the Enterprise Unit.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.